ライフサイエンスコーパス: cerivastatin

1 lowing 7 and 14 daily doses of 0.5 or 1mg/kg cerivastatin.

2 eeks of therapy with either 0.4 or 0.8 mg of cerivastatin.

3 also made to the first year of marketing of cerivastatin.

4 lipidemic rabbits (cerivastatin group, n=10, cerivastatin 0.6 mg x kg(-1) x d(-1); control group, n=9

5 5% confidence interval [CI], 0.20-0.84); for cerivastatin, 5.34 (95% CI, 1.46-13.68); and for fibrate

6 udy, rats receiving 14 daily doses of 1mg/kg cerivastatin (a myotoxic dose) had 6- and 2-fold elevati

7 We investigated the effect of the statins cerivastatin and atorvastatin on angiogenesis in vitro a

8 Cerivastatin and fenofibrate reduce LDLIII concentration

9 ontraindication about the concomitant use of cerivastatin and gemfibrozil to the package insert for m

10 clinical drug-drug interactions (e.g., with cerivastatin and repaglinide), which are more than expec

11 over study compared the effects of a statin (cerivastatin) and a fibrate (fenofibrate) on LDLIII and

12 inding affinity of fluvastatin, pravastatin, cerivastatin, and atorvastatin is the entropy change.

13 Cerivastatin, as well as other statins, also reduced RAN

14 atin) and four type II statins (fluvastatin, cerivastatin, atorvastatin, and rosuvastatin).

15 In contrast, cerivastatin, atorvastatin, or simvastatin concentration

16 The recent withdrawal of cerivastatin because of deaths from rhabdomyolysis, of w

17 is, of which 25% were related to gemfibrozil-cerivastatin combination therapy, has focused attention

18 Cerivastatin combined with fibrate conferred a risk of a

19 Mean plasma cerivastatin concentrations were 0.0 (control), 10.1 (lo

20 (atorvastatin, lovastatin, simvastatin, and cerivastatin) (CYP3A4-MET) or others (pravastatin and fl

21 Finally, high-dose cerivastatin decreased tumor growth and tumor vasculariz

22 Cerivastatin demonstrated a time-dependent effect on NO

23 , 1 to 65 months), statin therapy (excluding cerivastatin) did not result in significant absolute inc

24 Cerivastatin diminished accumulation of macrophages in a

25 and to 1035 (95% CI, 389-2117) for combined cerivastatin-fibrate use.

26 in users of this combination therapy, and a cerivastatin-gemfibrozil interaction was supported by th

27 e Watanabe heritable hyperlipidemic rabbits (cerivastatin group, n=10, cerivastatin 0.6 mg x kg(-1) x

28 n low-dose (P<0.05) and high-dose (P<0.0001) cerivastatin groups compared with controls, with concomi

29 tatin (low dose), or chow containing 125 ppm cerivastatin (high dose).

30 ex-, dose- and time-dependent development of cerivastatin-induced myotoxicity.

31 Cerivastatin inhibits betaAR-stimulated activation of Ra

32 Cerivastatin likewise inhibited the betaAR-stimulated ac

33 either control chow, chow containing 25 ppm cerivastatin (low dose), or chow containing 125 ppm ceri

34 ted that compared with atorvastatin calcium, cerivastatin monotherapy substantially increased the ris

35 rhabdomyolysis associated with high doses of cerivastatin monotherapy.

36 on, 37.3% for 0.4 mg and 42.2% for 0.8 mg of cerivastatin), no clear dose-response effect of cerivast

37 ivastatin), no clear dose-response effect of cerivastatin on CRP was observed, nor was there any subs

38 ined effect (after approximately 6 hours) of cerivastatin on endothelium was associated with an appro

39 cantly inhibited with high concentrations of cerivastatin or atorvastatin (2.5 mg x kg(-1) x d(-1)).

40 7 to 12.7 for patients who were treated with cerivastatin plus fibrate.

41 Cerivastatin reduced cholesterol (21%, P: < 0.01), trigl

42 Cerivastatin reduced the number of macrophages expressin

43 Fenofibrate but not cerivastatin reduces remnant lipoproteins.

44 Overall, cerivastatin resulted in a 13.3% reduction in median CRP

45 Mevalonic acid depletion (induced by 100 nm cerivastatin) significantly inhibited these IGF protecti

46 Cerivastatin stimulated NO release at a favorable rate a

47 ct evidence to prove that in the presence of cerivastatin, the NOS system in endothelium operates wit

48 icantly reduced within 8 weeks of initiating cerivastatin therapy in a lipid-independent manner.

49 mulation in rabbit atheroma, we administered cerivastatin to immature Watanabe heritable hyperlipidem

50 Cerivastatin treatment (>or=0.01 micromol/L) also reduce

51 III concentration was 187 +/- 85 mg/dl after cerivastatin treatment and 133 +/- 95 mg/dl after fenofi

52 Plasma LDLIII reduction with cerivastatin treatment correlated with LDL-C reduction (

53 -1, MMP-3, MMP-9, and TF also decreased with cerivastatin treatment.

54 Although only a small percentage of cerivastatin users also took gemfibrozil, approximately

55 Cerivastatin was associated with a 10-fold higher incide

56 In the published literature, cerivastatin was associated with much larger risks of rh

57 to assess the risk of rhabdomyolysis, until cerivastatin was removed from the market in August 2001.

58 the initial effect, the sustained effect of cerivastatin was shown at concentrations approximately 1

59 Cerivastatin was the most commonly implicated statin.

60 exposure to the HMG-CoA reductase inhibitor cerivastatin were undertaken to evaluate its potential e